Homocysteine, b vitamins, and vascular-access thrombosis in patients treated with hemodialysis

American Journal of Kidney Diseases

Volumn 32, Issue 3, 1998, Pages 475-481

  Tamura, Tsunenobu ^a   Bergman, Suzanne M ^a   Morgan, Sarah L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

B vitamins; End stage renal disease; Hemodialysis; Homocysteine; Vascular access thrombosis

Indexed keywords

CYANOCOBALAMIN; HOMOCYSTEINE; PYRIDOXINE;

ADULT; ARTICLE; BLOOD VESSEL GRAFT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MALE; THROMBOSIS;

EID: 0031715050     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9740165     Document Type: Article

References (35)

1. Robins AJ, Milewczyk BK, Booth EM, Mallick NP: Plasma amino acid abnormalities in chronic renal failure. Clin ChimActa 42:215-217, 1972
2. Laidlaw SA, Smolin LA, Davidson WD, Kopple JD: Sulfur amino acids in maintenance hemodialysis patients. Kidney Int 32:S-191-S-196, 1987 (suppl 22)
3. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37:697-701, 1988
4. Chauveau P, Chadefaux B, Cloudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43:S-72-S-77, 1993 (suppl 41)
5. Arnadottir M, Brattström L, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40:236-240, 1993
6. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PWF, Selhub J: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 114:93-103, 1995
7. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Seihub J, Rosenberg IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147-152, 1996
8. Tamura T, Johnston KE, Bergman SM: Homocysteine and folate concentrations in blood from patients treated with hemodialysis. J Am Soc Nephrol 7:2414-2418, 1996
9. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H: The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56:41-46, 1996
10. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW: Hyperhomocysteinemia confers an independent increased risk factor of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743-2748, 1996
11. Guttormsen AB, Ueland PM, Svarstad E, Refsum H: Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 52:495-502, 1997
12. Green R, Jacobsen DW: Clinical implications of hyperhomocysteinemia, in Bailey LB, (ed): Folate in Health and Disease, chap 4. New York, NY, Marcel Dekker, 1995, pp 75-122
13. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci M: High prevalence of homocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14:1080-1083, 1994
14. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ: Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 345:882-885, 1995
15. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van der Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet 10:111-113, 1995
16. Fan P-Y, Schwab SJ: Hemodialysis vascular access, in Henrich WL (ed): Principles and Practice of Dialysis, chap 3. Baltimore, MD, Williams & Wilkins, 1994, pp 22-37
17. Stabler SP, Marcell PD, Podell ER, Allen RH: Quantitation of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal Biochem 162:185-196, 1987
18. Tamura T: Microbiological assay of folates, in Picciano MF, Stokstad ELR, Gregory JF III (eds): Folic Acid Metabolism in Health and Disease. Contemporary Issues in Clinical Nutrition, vol 13. New York, NY, Wiley-Liss, 1990, pp 121-137
19. Tamura T, Freeberg LE, Cornwell PC: Inhibition by EDTA of growth of Lactobacillus casei in the folate micro-biological assay and its reversal by added manganese or iron. Clin Chem 36:1993, 1990
20. Camp VM, Chipponi J, Faraj BA: Radioenzymatic assay for direct measurement of pyridoxal-5′-phosphate. Clin Chem 29:642-644, 1983
21. Tamura, Soong S-J, Sauberlich HE, Hatch KD, Cole P, Butterworth CE, Jr: Evaluation of the deoxyuridine suppression test by using whole blood samples from folic acid-supplemented subjects. Am J Clin Nutr 51:80-86, 1990
22. Irvine C, Wilson YG, Currie IC, McGrath C, Scott J,. Day A, Stansbie D, Baird RN, Lamont PM: Hyperhomocysteinaemia is a risk factor for vein graft stenosis. Eur J Vasc Endovasc Surg 12:304-309, 1996
23. Eritsland J, Arnesen H, Seljeflot I, Abdelnoor M, Grønseth K, Berg K, Malinow MR: Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting. Am J Cardiol 74:1099-1102, 1994
24. 6 and erythropoietin. Am J Nephrol 13:464-466, 1993
25. Chueng WC, Lo CY, Lo WK, Ip M, Cheng IKP: Isoniazid induced encephalopathy in dialysis patients. Tuber Lung Dis 74:136-139, 1993
26. Siskind MS, Thienemann D, Kirklin L: Isoniazid-induced neurotoxicity in chronic dialysis patients: Report of three cases and a review of the literature. Nephron 64:303-306, 1993
27. Descombes E, Hanck AB, Fellay G: Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int 43:1319-1328, 1993
28. Kasama R, Koch T, Canals-Navas C, Pitone JM: Vitamin B6 and hemodialysis: The impact of high-flux/high-efficiency dialysis and review of literature. Am J Kidney Dis 27:680-686, 1996
29. 6 deficiency in uremia. Am J Clin Nutr 28:950-957, 1975
30. Miller JW, Ribaya-Mercedo JD, Russell RM, Shepard DC, Morrow FD, Cochaty EF, Sadowsky JA, Gershoff SN, Selhub J: Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 55:1154-1160, 1992
31. Stevenson RE, Schwartz CE, Du Y-Z, Adams MJ, Jr: Differences in methylenetetrahydrofolate reductase genotype frequencies, between whites and blacks. Am J Hum Genet 60:229-230, 1997
32. Motulsky AG: Nutritional ecologenetics: Homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Med Genet 58:17-20, 1996
33. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93:7-9, 1996
34. Bostom AG, Shemin D, Chan J, Lapane K, Rozen R, Nadeau M, Jacques P, Selhub J: Folate status, a common mutation in methylene-tetrahydrofolate reductase, and fasting total plasma homocysteine levels in dialysis patients. J Am Soc Nepnrol 7:A1123, 1996
35. Födinger M, Mannhalter C, Wölfl G, Pabinger I, Müller E, Schumid R, Hörl WH, Sunder-Plassmann G: Mutation (677C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52:517-523, 1997